Canbi Pharma Tech Limited

What are the requirements for excipients in transdermal drug delivery systems?

Oct 20, 2025

When it comes to transdermal drug delivery systems, excipients play a crucial role. As an excipient supplier, I've got a pretty good understanding of what's needed. In this blog, I'll break down the requirements for excipients in these systems.

Solubility and Compatibility

First off, solubility is key. Excipients need to be able to dissolve the active pharmaceutical ingredient (API) effectively. This ensures that the drug can be evenly distributed in the formulation and be released in a controlled manner. For example, if we're talking about a lipophilic drug, we need an excipient that can dissolve it well in the lipid - based matrix of a transdermal patch.

Compatibility is another big deal. The excipient has to be compatible with the API and other components in the formulation. There shouldn't be any chemical reactions between them that could degrade the drug or change its properties. For instance, some excipients might react with acidic or basic drugs, so we've got to choose carefully. If an excipient is not compatible, it could lead to issues like precipitation, which would mess up the drug delivery process.

Permeation Enhancement

One of the main challenges in transdermal drug delivery is getting the drug through the skin. That's where permeation enhancers come in. Excipients can act as permeation enhancers to increase the skin's permeability to the drug. They work by different mechanisms, such as disrupting the lipid bilayer of the stratum corneum, the outermost layer of the skin.

Some common types of permeation - enhancing excipients include fatty acids, alcohols, and surfactants. Fatty acids, like oleic acid, can interact with the lipids in the stratum corneum and increase their fluidity, making it easier for the drug to pass through. Alcohols, such as ethanol, can also disrupt the lipid structure and enhance drug permeation. Surfactants can reduce the surface tension between the drug and the skin, facilitating its penetration.

We offer some great excipients for permeation enhancement. For example, Mpeg - dppe has shown excellent results in enhancing the permeation of certain drugs. It can modify the skin's barrier function in a way that allows more of the drug to get through.

PCBTh-co-ThSHMPEG-DPPE

Stability and Shelf - Life

Excipients need to contribute to the stability of the transdermal drug delivery system. They should protect the API from degradation due to factors like light, heat, and moisture. For example, antioxidants can be added as excipients to prevent the oxidation of the drug. If a drug is prone to oxidation, an antioxidant excipient can help maintain its potency over time.

The excipient should also have good stability on its own. It shouldn't break down or change its properties during storage. This is important for ensuring the consistency of the drug delivery system. We've developed excipients like Pcbth - co - thsh that are known for their high stability. They can withstand different storage conditions and keep the drug formulation intact.

Biocompatibility

Since transdermal drug delivery systems come into direct contact with the skin, the excipients used must be biocompatible. They shouldn't cause any irritation, allergic reactions, or other adverse effects on the skin. Biocompatibility is especially important for long - term use of transdermal patches.

We test our excipients thoroughly to ensure they meet the biocompatibility standards. For example, Mpeg - cl#1 - 50hr has been evaluated in various in - vitro and in - vivo studies, and it has shown excellent biocompatibility with the skin. This means that patients can use transdermal products containing this excipient without worrying about skin problems.

Physical and Chemical Properties

The physical and chemical properties of excipients also matter a lot. Their viscosity, density, and melting point can affect the manufacturing process of transdermal drug delivery systems. For example, if an excipient has a very high viscosity, it might be difficult to mix it with other components in the formulation.

The chemical properties, such as pH and reactivity, also need to be considered. The pH of the excipient can influence the solubility and stability of the API. And as I mentioned before, reactivity should be carefully controlled to avoid any unwanted chemical reactions.

Regulatory Compliance

In the pharmaceutical industry, regulatory compliance is non - negotiable. Excipients used in transdermal drug delivery systems must meet all the relevant regulatory requirements. This includes safety, quality, and labeling standards. We make sure that all our excipients are compliant with the regulations set by different countries and regions. This gives our customers peace of mind when using our products in their transdermal formulations.

Cost - Effectiveness

Last but not least, cost - effectiveness is an important factor. Pharmaceutical companies are always looking for ways to reduce costs without sacrificing the quality of their products. As an excipient supplier, we understand this need. We strive to offer high - quality excipients at competitive prices. By choosing our excipients, companies can save on production costs while still getting a reliable product for their transdermal drug delivery systems.

If you're in the business of developing transdermal drug delivery systems and are looking for high - quality excipients that meet all the requirements I've mentioned, we'd love to hear from you. Whether you need excipients for permeation enhancement, stability, or biocompatibility, we've got the solutions. Reach out to us for a consultation and let's discuss how we can work together to create the best transdermal products.

References

  1. Guy, R. H., & Hadgraft, J. (Eds.). (2002). Transdermal drug delivery: Principles and practice. CRC press.
  2. Osborne, D. W., & Amann, A. J. (2009). Pharmaceutical excipients. Informa Healthcare.
  3. Singh, T. R., & Roberts, M. S. (2006). Permeation enhancers in transdermal drug delivery. International journal of pharmaceutics, 318(1 - 2), 1 - 18.
goTop